Drug resistance in cancer: An overview

Cancers

Volumn 6, Issue 3, 2014, Pages 1769-1792

  Housman, Genevieve ^a   Byler, Shannon ^b   Heerboth, Sarah ^b   Lapinska, Karolina ^b   Longacre, McKenna ^c   Snyder, Nicole ^b   Sarkar, Sibaji ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Cancer progenitor cells; Combination therapy; Drug resistance; Epigenetics; Methylation; Review

Indexed keywords

ABC TRANSPORTER; ABELSON KINASE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; CYTARABINE; CYTOCHROME P450; DNA METHYLTRANSFERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PLATINUM COMPLEX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB;

APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CELL HETEROGENEITY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG EFFICACY; DRUG INACTIVATION; DRUG TARGET ALTERATION; DRUG TRANSPORT; ENZYME ACTIVITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; METASTASIS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84923082324     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6031769     Document Type: Review

References (112)

1. Zahreddine, H.; Borden, K.L. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol. 2013, 4, 28.
2. Sampath, D.; Cortes, J.; Estrov, Z.; Du, M.; Shi, Z.; Andreeff, M.; Gandhi, V.; Plunkett, W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006, 107, 2517–2574.
3. Michael, M.; Doherty, M.M. Tumoral drug metabolism: Overview and its implications for cancer therapy. J. Clin. Oncol. 2005, 23, 205–229.
4. Plastaras, J.; Guengerich, F.; Nebert, D.; Marnett, L. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J. Biol. Chem. 2000, 275, 11784–11790.
5. Shen, H.; He, M.; Liu, H.; Wrighton, S.; Wang, L.; Guo, B.; Li, C. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos. 2007, 35, 1292–1300.
6. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25, 1679–1691.
7. Mehta, K.; Fok, J.Y. Targeting transglutaminase-2 to overcome chemoresistance in cancer cells. In Drug Resistance in Cancer Cells; Mehta, K., Bates, S.E., Siddik, Z.H., Eds.; Springer: New York, NY, USA, 2009; pp. 95–114.
8. Rivlin, N.; Brosh, R.; Oren, M.; Rotter, V. Mutations in the p53 tumor suppressor gene. Genes Cancer 2011, 2, 466–474.
9. Aas, T.; Børresen, A.; Geisler, S.; Smith-Sørensen, B.; Johnsen, H.; Varhaug, J.; Akslen, L.; Lønning, P. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996, 2, 811–814.
10. Soengas, M.S.; Alarcón, R.M.; Yoshida, H.; Giaccia, A.J.; Hakem, R.; Mak, T.W.; Lowe, S.W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999, 284, 156–159.
11. Townsend, D.M.; Tew, K.D. The role of glutathione-S-transferase in anticancer drug resistance. Oncogene 2003, 22, 7369–7375.
12. Manolitsas, T.P.; Englefield, P.; Eccles, D.M.; Campbell, I.G. No association of a 306 bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br. J. Cancer 1997, 75, 1397–1399.
13. Cumming, R.C.; Lightfoot, J.; Beard, K.; Youssoufian, H.; O’Brien, P.J.; Buchwald, M. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat. Med. 2001, 7, 814–820.
14. Holohan, C.; van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. 2013, 13, 714–726.
15. Gagnon, J.; Bernard, O.; Villeneuve, L.; Têtu, B.; Guillemette, C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin. Cancer Res. 2006, 12, 1850–1858.
16. Stavrovskaya, A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc.) 2000, 65, 95–106.
17. Hinds, M.; Deisseroth, K.; Mayes, J.; Altschuler, E.; Jansen, R.; Ledley, F.; Zwelling, L. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine resistant form of topoisomerase II. Cancer Res. 1991, 51, 4729–4731.
18. Zwelling, L.; Hinds, M.; Chan, D.; Mayes, J.; Sie, K.; Parker, E.; Silberman, L.; Radcliffe, A.; Beran, M.; Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug resistant form of topoisomerase II. J. Biol. Chem. 1989, 264, 16411–16420.
19. Slamon, D.; Godolphin, W.; Jones, L.; Holt, J.; Wong, S.; Keith, D.; Levin, W.; Stuart, S.; Udove, J.; Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 4905, 707–712.
20. Slamon, D.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783–792.
21. Bell, D.; Gore, I.; Okimoto, R.; Godin-Heymann, N.; Sordella, R.; Mulloy, R.; Sharma, S.; Brannigan, B.; Mohapatra, G.; Settleman, J., et al. Inherited susceptibility to lung cancer may be associated with the T790 drug resistance mutation in EGFR. Nat. Genet. 2005, 37, 1315–1316.
22. Kobyashi, S.; Boggon, T.; Dayaram, T.; Janne, P.; Kocher, O.; Meyerson, M.; Johnson, B.; Eck, M.; Tenen, D.; Halmos, B. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786–792.
23. Chen, Y.; Takita, J.; Choi, Y.; Kato, M.; Ohira, M.; Sanada, M.; Wang, L.; Soda, M.; Kikuchi, A.; Igarashi, T., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 7215, 971–974.
24. Zhang, N.; Yin, Y.; Xu, S.J.; Chen, W.S. 5-Fluorouracil: Mechanisms of resistance and reversal strategies. Molecules 2008, 13, 1551–1569.
25. Palmberg, C.; Koivisto, P.; Hyytinen, E.; Isola, J.; Visakorpi, T.; Kallioniemi, O.; Tammela, T. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur. J. Urol. 1997, 31, 216–219.
26. Dieras, V.; Vincent-Salomon, A.; Degeorges, A.; Beuzeboc, P.; Mignot, L.; de Cremoux, P. Trastuzumab (Herceptin) and breast cancer: Mechnisms of resistance. Bull Cancer 2007, 94, 259–266.
27. Berns, K.; Horlings, H.; Hennessy, B.; Madiredjo, M.; Hijmans, M.; Beelen, K.; Linn, S.; Gonzalez-Angulo, A.; Stemke-Hale, K.; Hauptmann, M., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12, 395–402.
28. Browne, B.C.; Crown, J.; Venkatesan, N.; Duffy, M.J.; Clynes, M.; Slamon, D.; O’Donovan, N. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann. Oncol. 2011, 22, 68–73.
29. Razis, E.; Bobos, M.; Kotoula, V.; Eleftheraki, A.G.; Kalofonos, H.P.; Pavlakis, K.; Papakostas, P.; Aravantinos, G.; Rigakos, G.; Efstratiou, I., et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res. Treat. 2011, 128, 447–456.
30. Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P.N.; Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 2001, 293, 876–880.
31. Al-Jamal, H.A.; Asmaa, M.J.; Yong, A.C.; Asan, J.M.; Hassan, R.; Johan, M.F. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Asian Pac. J. Cancer Prev. 2014, 15, 4555–4561.
32. Hirayama, C.; Watanabe, H.; Nakashima, R.; Nanbu, T.; Hamada, A.; Kuniyasu, A.; Nakayama, H.; Kawaguchi, T.; Saito, H. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharm. Res. 2008, 25, 827–835.
33. Nambu, T.; Araki, N.; Nakagawa, A.; Kuniyasu, A.; Kawaguchi, T.; Hamada, A.; Saito, H. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci. 2010, 101, 137–142.
34. Shou, J.; Massarweh, S.; Osborne, C.K.; Wakeling, A.E.; Ali, S.; Weiss, H.; Schiff, R. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 2004, 96, 926–935.
35. Massarweh, S.; Osborne, C.K.; Creighton, C.J.; Qin, L.; Tsimelzon, A.; Huang, S.; Weiss, H.; Rimawi, M.; Schiff, R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68, 826–833.
36. Chang, G.; Roth, C. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001, 293, 1793–1800.
37. Sauna, Z.; Ambudkar, S. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J. Biol. Chem. 2001, 276, 11653–11661.
38. Borst, P.; Elferink, O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537–592.
39. Schinkel, A.; Smit, J.; van Tellingen, O.; Beijnen, J.; Wagenaar, E.; van Deemter, L.; Mol, C.; van der Valk, M.; Robanus-Maandag, R.; te Riele, H., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491–502.
40. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48–58.
41. Szakas, G.; Annereau, J.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K.; Reinhold, W.; Guo, Y.; Kruh, G.; Reimers, M., et al. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6, 129–137.
42. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A.; Karlsson, J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 2007, 35, 1333–1340.
43. Abolhoda, A.; Wilson, A.; Ross, H.; Danenberg, P.V.; Burt, M.; Scotto, K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 1999, 5, 3352–3356.
44. Haber, M.; Smith, J.; Bordow, S.; Flemming, C.; Cohn, S.; London, W.; Marshall, G.; Norris, M. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of neuroblastoma. J. Clin. Oncol. 2006, 24, 1546–1553.
45. Yanase, K.; Tsukahara, S.; Asada, S.; Ishikawa, E.; Imai, Y.; Sugimoto, Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 2004, 3, 1119–1125.
46. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665–15670.
47. Imai, Y.; Ishikawa, E.; Asada, S.; Sugimoto, Y. Estrogenmediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res. 2005, 65, 596–604.
48. Mutoh, K.; Tsukahara, S.; Mitsuhashi, J.; Katayama, K.; Sugimoto, Y. Estrogen-mediated post transcriptional downregulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci. 2006, 97, 1198–1204.
49. Katayama, K.; Yoshioka, S.; Tsukahara, S.; Mitsuhashi, J.; Sugimoto, Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol. Cancer Ther. 2007, 6, 2092–2102.
50. Fukuyo, Y.; Hunt, C.R.; Horikoshi, N. Geldanamycinand its anticancer activities. Cancer Lett. 2010, 290, 24–35.
51. Bonanno, L.; Favaretto, A.; Rosell, R. Platinum drugs and DNA repair mechanism in lung cancer. Anticancer Res. 2014, 34, 493–502.
52. Olaussen, K.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Helmut, P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355, 983–991.
53. Selvakumaran, M.; Pisarcik, D.; Bao, R.; Yeung, A.; Hamilton, T. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63, 1311–1316.
54. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. 2012, 12, 801–817.
55. Esteller, M. Epigenetic lesions causing genetic lesions in human cancer: Promoter hypermethylation of DNA repair genes. Eur. J. Cancer 2000, 36, 2294–2300.
56. Goode, E.; Ulrich, C.; Potter, J. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 1513–1530.
57. Maier, P.; Spier, I.; Laufs, S.; Veldwijk, M.R.; Fruehauf, S.; Wenz, F.; Zeller, W.J. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K). Gene Ther. 2010, 17, 389–399.
58. Blanc, J.L.; Wager, M.; Guilhot, J.; Kusy, S.; Bataille, B.; Chantereau, T.; Lapierre, F.; Larsen, C.J.; Karayan-Tapon, L. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J. Neurooncol. 2004, 68, 275–283.
59. Rabik, C.; Fishel, M.; Holleran, J.; Kasza, K.; Kelley, M.; Egorin, M.; Dolan, M. Enhancement of cisplatin cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J. Pharmacol. Exp. Ther. 2008, 327, 442–452.
60. Gegi, M.; Diserens, A.; Gorlia, T.; Hamou, M.; de Tribolet, N.; Weller, M.; Kros, J.; Hainfellner, J.; Mason, W.; Mariani, L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352, 997–1003.
61. Dong, X.; Liu, R.; Chen, W. Correlation of promoter methylation in MGMT gene with glioma risk and prognosis: A meta-analysis. Mol. Neurobiol. 2014, doi:10.1007/s12035-014-8760-3.
62. Frew, A.J.; Lindemann, R.K.; Martin, B.P. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl. Acad. Sci. USA 2008, 105, 11317–11322.
63. Soria, J.; Smit, E.; Khayat, D.; Besse, B.; Yang, X.; Hsu, C.; Reese, D.; Wiezorek, J.; Blackhall, F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumanb in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 1527–1533.
64. Mataga, M.; Rosenthal, S.; Heerboth, S.; Devalapalli, A.; Kokolus, S.; Evans, L.R.; Longacre, M.; Housman, G.; Sarkar, S. Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitors. Anticancer Res. 2012, 32, 2523–2530.
65. Sarkar, S.; Faller, D.V. T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleoties 2011, 21, 47–53.
66. Sarkar, S.; Faller, D.V. Telomere-homilogous G-rich oligonucleotides sensitize human ovarian cancer cells by combination therapy. Nucleic Acid Ther. 2013, 23, 167–174.
67. Sasaki, K.; Tsuno, N.H.; Sunami, E.; Tsurita, G.; Kawai, K.; Okaji, Y.; Nishikawa, T.; Shuno, Y.; Hongo, K.; Hiyoshi, M., et al. Chloroquine potentiates the anticancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010, 10, e370.
68. Cook, K.L.; Wärri, A.; Soto-Pantoja, D.R.; Clarke, P.A.G.; Cruz, M.I.; Zwart, A.; Clarke, R. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin. Cancer Res. 2014, 20, 3222–3232.
69. Shang, Y.; Cai, X.; Fan, D. Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr. Cancer Drug Targets 2013, 13, 915–929.
70. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 2010, 29, 4741–4751.
71. Chaffer, C.; Brueckmann, I.; Scheel, C.; Kaestli, A.; Wiggins, P.; Rodrigues, L.; Brooks, M.; Reinhardt, F.; Su, Y.; Polyak, K., et al. Normal and neoplastic nonstem cells can spontaneously covert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108, 7950–7955.
72. Chaffer, C.; Weinberg, R. A perspective on Cancer Cell Metastasis. Science 2011, 331, 1559–1564.
73. Sarkar, S.; Horn, G.; Moulton, K.; Oza, A.; Byler, S.; Kokolus, S.; Longacre, M. Cancer development, progression and therapy: An epigenetic overview. Int. J. Mol. Sci. 2013, 14, 21087–21113.
74. Byler, S.; Goldgar, S.; Heerboth, S.; Leary, M.; Housman, G.; Moulton, K.; Sarkar, S. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 2014, 34, 1071–1077.
75. Byler, S.; Sarkar, S. Do epigenetic drug treatments hold the key to killing cancer progenitor cells? Epigenomics 2014, 6, 161–165.
76. Lenisak, D.; Xu, Y.; Deschenes, J.; Lai, R.; Thoms, J.; Murray, D.; Gosh, S.; Mackey, J.R.; Sabri, S.; Abdulkarim, B. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 2009, 69, 8620–8628.
77. Sarkar, S.; Svoboda, M.; de-Beaumont, R.; Freedman, A. The role of AKT and RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk. Lymphoma 2002, 43, 1663–1671.
78. Wendt, M.K.; Smith, J.A.; Schiemann, W.P. Transforming growth factor-ß-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010, 29, 6485–6498.
79. Carraway, K.L., 3rd; Sweeney, C. Co-opted integrin signaling in ErbB2-induced mammary tumor progression. Cancer Cell 2006, 10, 93–95.
80. Bates, R.C.; Mercurio, A.M. The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol. Ther. 2005, 4, 365–370.
81. Galliher, A.J.; Schiemann, W.P. ß3 integrin and Src facilitate transforming growth factor-ß mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2006, 8, R42.
82. Shibue, T.; Weinberg, R.A. Integrin ß1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl. Acad. Sci. USA 2009, 106, 10290–10295.
83. Witz, I.P. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev. 2008, 27, 19–30.
84. Paschos, K.A.; Canovas, D.; Bird, N.C. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell. Signal. 2009, 21, 665–674.
85. Laubli, H.; Borsig, L. Selectins promote tumor metastasis. Semin. Cancer Biol. 2010, 20, 169–177.
86. Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10, 9–22.
87. Bendas, G.; Borsig, L. Cancer cell adhesion and metastasis: Selectins, integrins, and the inhibitory potential of heparins. Int. J. Cell Biol. 2012, 2012, doi:10.1155/2012/676731.
88. Barkan, D.; Kleinman, H.; Simmons, J.L.; Asmussen, H.; Kamaraju, A.K.; Hoenorhoff, M.J.; Liu, Z.Y.; Costes, S.V.; Cho, E.H.; Lockett, S., et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 2008, 68, 6241–6250.
89. Ning, Y.; Gerger, A.; Zhang, W.; Hanna, D.L.; Yang, D.; Winder, T.; Wakatsuki, T.; Labonte, M.J.; Stintzing, S.; Volz, N., et al. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol. Cancer Ther. 2014, 13, 528–539.
90. Bégué, E.; Jean-Louis, F.; Bagot, M.; Jauliac, S.; Cayuela, J.M.; Laroche, L.; Parquet, N.; Bachelez, H.; Bensussan, A.; Courtois, G., et al. Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. Blood 2012, 120,143–154.
91. Staussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z.R.; Du, J.; Davis, A.; Mongare, M.M.; Gould, J.; Frederick, D.T., et al. Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487, 500–504.
92. Parkin, B.; Ouillette, P.; Li, Y.; Keller, J.; Lam, C.; Roulston, D.; Li, C.; Shedden, K.; Malek, S.N. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 2013, 121, 369–377.
93. Navin, N.; Krasnitz, A.; Rodgers, L.; Cook, K.; Meth, J.; Kendall, J.; Riggs, M.; Eberling, Y.; Troge, J.; Grubor, V., et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010, 20, 68–80.
94. Campbell, P.; Yachida, S.; Mudie, L.; Stephens, P.; Pleasance, E.; Stebbings, L.; Morsberger, L.; Latimer, C.; McLaren, S.; Lin, M., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467, 1109–1113.
95. Baker, E.K.; El-Osta, A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp. Cell Res. 2003, 290, 177–194.
96. Kantharidis, P.; El-Oska, A.; de Silva, M.; Wall, D.M.; Hu, X.F.; Slater, A.; Nadalin, G.; Parkin, J.D.; Zalcberg, J.R. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin. Cancer Res. 1997, 3, 2025–2032.
97. Plumb, J.A.; Strathdee, G.; Sludden, J.; Kaye, S.B.; Brown, R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60, 6039–6044.
98. Arnold, C.N.; Goel, A.; Boland, C.R. Role of MLH1 promoter hypermethylation in drug resistance to 5-flurouracil in colorectal cancer cell lines. Int. J. Cancer 2003, 106, 66–73.
99. Bearzatto, A.; Szadkowski, M.; Macpherson, P.; Jiricny, J.; Karran, P. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res. 2000, 60, 3262–3270.
100. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343, 1350–1354.
101. Worm, J.; Kirkin, A.F.; Dzhandzhugazyan, K.N.; Guldberg, P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J. Biol. Chem. 2001, 276, 39990–40000.
102. Chang, H.G.; Kim, S.J.; Chung, K.W.; Noh, D.Y.; Kwon, Y.; Lee, E.S.; Kang, H.S. Tamoxifen-resistant breast cancer show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J. Mol. Med. 2005, 83, 132–139.
103. Christmann, M.; Pick, M.; Lage, H.; Schadendorf, D.; Kaina, B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int. J. Cancer 2001, 92, 123–129.
104. Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; von Hoff, D.D. 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells. Anticancer Res. 1999, 19, 1285–1291.
105. Sarkar, S.; Abujamra, A.L.; Loew, J.E.; Forman, L.W.; Perrine, S.P.; Faller, D.V. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res. 2011, 31, 2723–2732.
106. Housman, G.; Mataga, A.M.; Devalapalli, A.; Heerboth, S.; Evans, L.R.; Sarkar, S. Demethylation and re-expression of tumor suppressor genes by HDAC inhibitors and calpain inhibitors in cancer cells: A study related to synergistic type growth inhibition and reduction of motility. The Epigenetics World Congress, MA, USA, April 2011; Abstract 206.
107. Sarkar, S.; Goldgar, S.; Byler, S.; Rosenthal, S.; Heerboth, S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: Sensitization of cancer cells by combination therapy. Epigenomics 2013, 5, 87–94.
108. Juergens, R.; Wrangle, J.; Vendetti, F.; Murphy, S.C.; Zhao, M.; Coleman, B.; Sebree, R.; Rodgers, K.; Hooker, C.M.; Franco, N., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1, 598–607.
109. Johannessen, C.M.; Johnson, L.A.; Piccioni, F.; Townes, A.; Frederick, D.T.; Donahue, M.K.; Narayan, R.; Flaherty, K.T.; Wargo, J.A.; Root, D.E., et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013, 504, 138–142.
110. Cacan, E.; Ali, M.W.; Boyd, N.H.; Hooks, S.B.; Greer, S.F. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One 2014, 9, e87455.
111. Sarkar, S.; Longacre, M.; Tatur, N.; Heerboth, S.; Lapinska, K. Histone deacetylases (HDACs): Function, mechanism, & inhibition. In Encyclopedia of Analytical Chemistry; Meyers, R.A., Ed.; John Wiley: Chichester, UK, 2014; pp. 1–9.
112. Heerboth, S.; Lapinska, K.; Snyder, N.; Leary, M.; Rollinson, S.; Sarkar, S. The use of epigenetic drugs in diseases: An overview. Genet. Epigenet. 2014, 6, 9–19.